Signature Equity Partners’s BridgeBio Pharma BBIO Stock Holding History

Signature Equity Partners’s Portfolio BBIO Stock Details BBIO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$1.42K	Buy	19 +13	+217%	+$911	﹤0.01%	1241
2026 Q1	$446	Hold	6	–	–	﹤0.01%	1392
2025 Q4	$459	Buy	+6	New	+$394	﹤0.01%	1537

Other funds holding BBIO

Jupiter Topco New York $245B AUM

KKRC

Kohlberg Kravis Roberts & Co New York $5.71B AUM 72.37% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

ACM

Aisling Capital Management New York $472M AUM 106.83% 1-Year Est. Return

Signature Equity Partners's BBIO Position: Q2 2026 in Review

Signature Equity Partners increased its BridgeBio Pharma (BBIO) stake by 217% in Q2 2026, buying an estimated $911 and bringing the position to 19 shares worth $1.42K. The position accounts for ﹤0.01% of the portfolio, ranked #1241.

Signature Equity Partners first reported a position in BBIO in Q4 2025 and has held it in 3 quarters since. 474 funds tracked by Wall St. Rank hold BBIO as of Q2 2026.

Signature Equity Partners held 19 shares of BridgeBio Pharma worth $1.42K as of Q2 2026.
Signature Equity Partners bought 13 BridgeBio Pharma shares in Q2 2026, an estimated $911.
BridgeBio Pharma made up ﹤0.01% of Signature Equity Partners's portfolio in Q2 2026, its #1241 holding.
Signature Equity Partners first reported a position in BridgeBio Pharma in Q4 2025 and has held it in 3 quarters since.
474 funds tracked by Wall St. Rank held BridgeBio Pharma as of Q2 2026.

Based on Signature Equity Partners's 13F filing for Q2 2026, filed 30 Jul 2026.